Anthony Quinn is CMO & EVP +1 at SYNAGEVA BIOPHARMA CORP (GEVA). They have made 1 open-market trade across 1 company since 2012, most recently 2016-04-12.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $100K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AGLE | BUY | 2016-04-12 | 2016-04-12 | $10.00 | $100K | -7.5% | -24.9% | -58.6% |
| GEVA | SELL · 10b5-1 | 2015-04-27 | 2015-04-29 | $110.00 | $1.1M | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2015-04-21 | 2015-04-23 | $108.00 | $1.1M | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2015-04-15 | 2015-04-17 | $105.00 | $1.1M | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2015-04-06 | 2015-04-08 | $93.76 | $2.8M | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2014-04-01 | 2014-04-03 | $83.53 | $1.7M | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-01-18 | 2013-01-23 | $50.08 | $473K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-01-16 | 2013-01-18 | $50.07 | $278K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2012-07-26 | 2012-07-30 | $50.20 | $376K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2012-07-19 | 2012-07-23 | $50.00 | $125K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2012-06-25 | 2012-06-27 | $40.65 | $1.1M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.